[Drug-induced movement disorders: tardive syndromes].
Persistent drug-induced movement disorders (tardive syndromes) remain an important clinical problem and consist of a variety of involuntary movements appearing in a patient exposed to a dopamine-blocking agent. The current state of knowledge on this topic is summarised in this article. Clinical aspects (tardive dyskinesia, tardive dystonia and other forms), prevalence, risk factors, prevention and management are discussed.
Blayac
Jean-Pierre
JP
Service de Pharmacologie Médicale et Toxicologie, Hôpital Lapeyronie, CHU de Montpellier, 34295 Montpellier, France. jp-blayac@chu-montpellier.fr
Pinzani
Véronique
V
Peyrière
Hélène
H
Hillaire-Buys
Dominique
D
D017109:Akathisia, Drug-Induced / Q000503:physiopathology; D018492:Dopamine Antagonists / Q000009:adverse effects*; D004409:Dyskinesia, Drug-Induced / Q000503:physiopathology* / Q000628:therapy; D004421:Dystonia / Q000139:chemically induced / Q000503:physiopathology; D006801:Humans; D009207:Myoclonus / Q000139:chemically induced; D011954:Receptors, Dopamine / Q000187:drug effects; D012701:Serotonin / Q000502:physiology; D020323:Tics / Q000139:chemically induced; D014202:Tremor / Q000139:chemically induced
D018492:Dopamine Antagonists; D011954:Receptors, Dopamine; D012701:Serotonin